Rethinking preeclampsia: six paradigm shifts in placental pathophysiology for maternal–foetal medicine
-
By
-
Can Bilginer
-
Ali Çetin
-
June 22, 2026
-
Clinical Scorecard: Reevaluating Preeclampsia: Six Key Changes in Placental Pathophysiology for Maternal-Fetal Health
At a Glance
| Category | Detail |
|---|
| Condition | Preeclampsia |
| Key Mechanisms | First-trimester villous origins, intervillous hyperoxia, metabolic and glycocalyx-based pathogenesis, steroid imbalance, reduced immune tolerance. |
| Target Population | Pregnant individuals at risk of preeclampsia. |
| Care Setting | Maternal-fetal medicine |
Key Highlights
- Preeclampsia affects 2-4% of pregnancies globally.
- Six paradigm shifts in understanding placental pathophysiology.
- Reconceptualization of preeclampsia as a first-trimester syndrome.
- Low-dose aspirin reduces preterm preeclampsia by approximately 60%.
- Need for earlier, multimodal risk assessment and biomarker panels.
Guideline-Based Recommendations
Diagnosis
- Consider the sFlt-1 to placental growth factor ratio for triage.
Management
- Initiate low-dose aspirin before 16 weeks of gestation.
Monitoring & Follow-up
- Utilize biomarker panels that capture metabolic and extracellular vesicle signatures.
Risks
- Preeclampsia contributes to significant maternal and perinatal morbidity and mortality.
Patient & Prescribing Data
Pregnant individuals at risk for preeclampsia.
Low-dose aspirin is effective in reducing the incidence of preterm preeclampsia.
Clinical Best Practices
- Adopt a multimodal approach for risk assessment in the first trimester.
- Reevaluate traditional models of preeclampsia pathophysiology.
Related Resources & Content
